Cargando…

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake. The aim of the study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laroni, Alice, Brogi, Davide, Morra, Vincenzo Brescia, Guidi, Leonello, Pozzilli, Carlo, Comi, Giancarlo, Lugaresi, Alessandra, Turrini, Renato, Raimondi, Debora, Uccelli, Antonio, Mancardi, Giovanni Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4005629/ https://www.ncbi.nlm.nih.gov/pubmed/24690227 http://dx.doi.org/10.1186/1471-2377-14-65

Ejemplares similares

Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study
por: Comi, Giancarlo, et al.
Publicado: (2020)

Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients
por: Serpero, Laura D., et al.
Publicado: (2013)

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
por: Comi, Giancarlo, et al.
Publicado: (2017)

CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis
por: Laroni, Alice, et al.
Publicado: (2020)

CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis
por: Schiavetti, Irene, et al.
Publicado: (2023)

Dramatic rebounds of MS during pregnancy following fingolimod withdrawal
por: Novi, Giovanni, et al.
Publicado: (2017)

Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study
por: Lugaresi, Alessandra, et al.
Publicado: (2012)

Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis
por: Petsas, Nikolaos, et al.
Publicado: (2019)

Different MRI patterns in MS worsening after stopping fingolimod
por: Lapucci, Caterina, et al.
Publicado: (2019)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
por: Gold, Ralf, et al.
Publicado: (2013)

Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis
por: Cellerino, Maria, et al.
Publicado: (2021)

Teriflunomide treatment reduces B cells in patients with MS
por: Gandoglia, Ilaria, et al.
Publicado: (2017)

Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study
por: Sbardella, Emilia, et al.
Publicado: (2009)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Regulatory Functions of Natural Killer Cells in Multiple Sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Metabolomic Changes in Patients Affected by Multiple Sclerosis and Treated with Fingolimod
por: Murgia, Federica, et al.
Publicado: (2023)

Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4
por: Centonze, Diego, et al.
Publicado: (2023)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
por: Doosti, Rozita, et al.
Publicado: (2021)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals’ perspective
por: Lus, Giacomo, et al.
Publicado: (2022)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
por: Coles, Alasdair J., et al.
Publicado: (2023)

Social Media and Multiple Sclerosis in the Posttruth Age
por: Lavorgna, Luigi, et al.
Publicado: (2017)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Fingolimod-Associated Macular Edema in the Treatment of Multiple Sclerosis
por: Khan, Asma A, et al.
Publicado: (2023)

Combining Clinical and Genetic Data to Predict Response to Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients: A Precision Medicine Approach
por: Ferrè, Laura, et al.
Publicado: (2023)

Assessment of Macular Function by Multifocal Electroretinogram in Patients with Multiple Sclerosis Treated with Fingolimod
por: Barbano, Lucilla, et al.
Publicado: (2021)

Assessing disability and relapses in multiple sclerosis on tele-neurology
por: Moccia, Marcello, et al.
Publicado: (2020)

Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice
por: De Angelis, Marcello, et al.
Publicado: (2020)

Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study
por: Pastò, Luisa, et al.
Publicado: (2012)

Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study
por: Ordoñez-Boschetti, Laura, et al.
Publicado: (2015)

Fingolimod (Gileyna, FTY720): Innovative treatment for multiple sclerosis
por: Pinki,, et al.
Publicado: (2011)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
por: Marriott, James J.
Publicado: (2011)

Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients
por: Farrokhi, Mehrdad, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_k6aij5bqipptltkh79gogc5fg8